Pricing
  1. JP-listed companies
  3. Financials
  4. Pretax margin (%)

(4893)

Market cap
¥6.4B
P/E ratio
Develops cancer immunotherapy treatments for solid tumors using proprietary PRIME technology that enhances immune cell activation and generates revenue through both in-house drug development and technology licensing.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Dec 31, 2025-15,822.3+24.78%
Dec 31, 2024-12,680+3462.69%
Dec 31, 2023-355.9+479.71%
Dec 31, 2022-61.4-92.20%
Dec 31, 2021-786.9+26.60%
Dec 31, 2020-621.5-5790.47%
Dec 31, 201910.9-85.73%
Dec 31, 201876.5

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat